Abstract 315P
Background
Cetuximab (an inhibitor of EGFR) is commonly utilized for the treatment of head and neck cancers. It has been employed in combination with radiation or multi-agent chemotherapy for locoregionally advanced and metastatic head and neck cancer respectively. This study explored the use of cetuximab plus an JAK1 inhibitor (JAK1i), which is a protein that is downstream in EGFR signaling, in order to test whether this dual inhibition could accentuate the effects of cetuximab.
Methods
Human head and neck squamous cell cancer cells (UM-SCC-6 cells) were cultured as previously described (Bonner JA et al., BMC Cancer 15:673). The JAK1 inhibitor (JAK1i) was obtained from Calbiochem, LaJolla, CA. Standard assays of immunoblots, proliferation, apoptosis and comet assays were utilized (Bonner JA et al., BMC Cancer 15:673).
Results
The combination of cetuximab (0.5 μg/ml) and JAK1i (1µM) resulted in greater inhibition of STAT-3 than either agent alone on immunoblot analysis. Likewise, the combination treatment resulted in greater inhibition of cell proliferation (at 72 hours), greater apoptosis and enhanced DNA double strand breaks (comet) compared to either agent given alone.
Conclusions
Cetuximab initially showed activity in head and neck cancer over 20 years ago. It is currently used in combination with radiation or chemotherapy for these patients. The results reported herein suggest that the anti-proliferative effects of cetuximab can be enhanced with the addition of JAK1 inhibition. Further work exploring the targeting of various steps in EGFR signaling is warranted in head and neck cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
James A. Bonner.
Funding
Has not received any funding.
Disclosure
J.A. Bonner: Honoraria (institution), Advisory / Consultancy: Bristol-Myers Squibb Company; Honoraria (institution), Advisory / Consultancy: Eli Lily and Company; Honoraria (institution), Advisory / Consultancy: Merck Serono; Honoraria (institution), Advisory / Consultancy: Cel-Sci. E. Yang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract